Boston Scientific's (BSX) Farapulse and Watchman products are expected to drive upside following the discontinuation of global sales of the Acurate transcatheter aortic valve replacements, Needham said in a note Wednesday.
The company announced earlier Wednesday it will discontinue sales of Acurate neo2 and Acurate Prime as well as halt efforts to secure US Food and Drug Administration and other market approvals after recent discussions with regulators led to increased clinical and regulatory requirements for Acurate products.
Needham said Boston Scientific expects to offset the impact of Acurate's shelving with other growth drivers such as Farapulse and Watchman as the company reiterated its outlook for Q2 and 2025.
"We view any weakness in BSX shares today as a buying opportunity given our expectation that Farapulse and Watchman continue to drive upside to consensus estimates," Needham said. "We expect the Champion trial results to be a major catalyst in H1 2026."
Needham has a buy rating on Boston Scientific, with a $115 price target.
Price: 104.73, Change: -1.45, Percent Change: -1.36
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。